Repare Therapeutics (RPTX)
(Delayed Data from NSDQ)
$2.91 USD
-0.10 (-3.32%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $2.91 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum D VGM
Price, Consensus and EPS Surprise
RPTX 2.91 -0.10(-3.32%)
Will RPTX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for RPTX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for RPTX
Repare Therapeutics Inc. (RPTX) Reports Q2 Loss, Lags Revenue Estimates
Theravance (TBPH) Q2 Loss Wider Than Expected, Revenues Rise Y/Y
RPTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
CRISPR Therapeutics (CRSP) Q2 Loss Wider Than Expected
Blueprint Medicines (BPMC) Down Despite Q2 Earnings Beat
Puma Biotechnology's (PBYI) Q2 Loss Narrower Than Expected
Other News for RPTX
Repare: Q4 2024 Is A Major Inflection Point With Lunresertib, Camonsertib Data
Repare Therapeutics Announces Strategic Reprioritization to Focus on Broad Clinical Portfolio
Repare to focus on clinical assets, cut 25% of workforce
Repare Therapeutics Announces Strategic R&D Focus and Workforce Reduction
Repare announces strategic reprioritization, to lay off 25% of workforce